Last Update 16 Jul 26
Fair value Increased 26%TWST: AI Drug Discovery Demand Will Shape Multi Year Upside Potential
Analyst Commentary
Bullish analysts covering Twist Bioscience have been revisiting their models, with a series of higher price targets and positive views on the company’s execution in life science tools and synthetic biology. Across recent research updates, the core themes are confidence in Twist Bioscience's positioning in key markets, interest in its exposure to next generation drug discovery, and a willingness to ascribe higher valuation multiples despite acknowledged risks.
Several firms have lifted their price targets into a US$95 to US$120 range while reiterating positive ratings. These moves have generally come alongside refreshed assumptions around revenue mix, margin progression, and the potential impact of new demand drivers such as AI related workflows and broader adoption of Twist Bioscience’s platform across drug discovery and development customers.
Not every analyst is leaning more positive. One firm has shifted to a more neutral, or "In Line," stance even as its price target moved to US$102 from US$66, citing prior stock gains and a desire to take some profits after a strong run. That more cautious tone sits alongside a broader group of bullish analysts who remain focused on longer term growth opportunities, execution against management plans, and potential upside if new growth drivers materialize.
Across the coverage, there is also recognition of sector level headwinds in biotech and academic spending and exposure to China, with some analysts preferring to see further evidence of demand resilience before turning more constructive on the wider life sciences tools group. Even so, Twist Bioscience continues to feature in research as one of the companies with what analysts view as differentiated positioning in promising markets.
Bullish Takeaways
- Bullish analysts have raised price targets on Twist Bioscience into a band that now reaches up to US$120, reflecting greater willingness to underwrite higher P/E assumptions tied to the company’s growth profile and execution to date.
- Several recent research updates keep positive ratings in place while lifting price targets, signaling continued confidence in Twist Bioscience’s ability to compete in life science tools and synthetic biology and to translate its product set into sustained top line expansion.
- Some bullish analysts highlight Twist Bioscience’s growing exposure to next generation drug discovery and development as a key upside driver, viewing that end market as an important support for premium valuation multiples if adoption trends remain favorable.
- Across coverage, Twist Bioscience is often grouped with companies that maintain what analysts describe as leading and differentiated positions in promising markets, which supports the case for a higher fair value range as the company executes on its growth plans.
What’s in the News for Twist Bioscience
- Several major investment firms raised their price targets for Twist Bioscience, citing momentum in AI related orders and positive trends in life science and diagnostic tools, with Evercore ISI moving to US$102 while rating the stock In Line, Guggenheim to US$107 with a Buy rating, and Barclays to US$95 with an Overweight rating (source: recent analyst reports).
- Twist Bioscience filed a US$200 million follow on equity offering as an at the market program for its common stock, providing an additional funding channel for corporate purposes (source: company filing).
- LenioBio announced a collaboration with Twist Bioscience that pairs LenioBio’s ALiCE cell free protein expression platform with Twist’s DNA manufacturing and automation, aimed at speeding the design build test cycle for AI driven protein and antibody work and expanding Twist’s protein expression capabilities (source: LenioBio announcement).
- Twist Bioscience expanded its clonal genes portfolio with an early access launch of Complex Genes, targeting structurally complex and highly engineered sequences that support AI enabled drug discovery and nucleic acid therapeutics, with stated acceptance of approximately 99.5% of clonal gene orders and 99.9% of all DNA products (source: company product announcement).
- Twist Bioscience held an Analyst and Investor Day, providing a dedicated forum for management updates and detailed discussion of the business (source: company event notice).
Valuation Changes for Twist Bioscience
- Fair Value Estimate, raised from $95 to $120, a step up of roughly 26% that puts Twist Bioscience at the upper end of recent analyst target ranges.
- Discount Rate, adjusted slightly lower from 7.23% to 7.18%, which gives a modest uplift to the present value of projected cash flows.
- Revenue Growth, nudged higher from 19.44% to 20.43%, reflecting a small increase in expected top line expansion for Twist Bioscience.
- Net Profit Margin, reduced from 18.92% to 17.97%, indicating slightly more conservative assumptions on future profitability.
- Future P/E, lifted from 60.35x to 78.16x, implying a higher valuation multiple being applied to Twist Bioscience’s earnings power.
Key Takeaways
- Twist's margin expansion and rapid product innovation are driving accelerating profitability and positioning the company for industry-leading financial performance.
- Expanding demand for synthetic biology, AI-driven drug discovery, and disruptive new markets sets the stage for resilient, compounding revenue and substantial long-term upside.
- Sustained pricing pressure, persistent unprofitability risk, execution challenges in new markets, volatile funding, and heightened regulatory or supply chain risks all threaten future profitability.
Catalysts
About Twist Bioscience- Manufactures and sells synthetic DNA-based products.
- While analyst consensus expects process improvements and product mix to lift gross margins moderately, the company's relentless execution has already delivered a leap from 31% to above 53% in just two years, with ongoing vertical integration and rapid product cycles positioning Twist to achieve industry-leading margins far above current forecasts-potentially transforming EBITDA and net income even faster than expected.
- Analysts broadly agree that Twist's best-in-class automated synthesis and strong commercial execution will drive robust revenue growth, yet this view may be conservative: the accelerating pace of customer wins, rapid new product rollouts, and expanding reach into "long tail" academic and industrial accounts is setting the stage for compounding, double-digit revenue expansion and highly resilient recurring revenue, especially as the company converts smaller accounts into scaled, sticky customers.
- Growing global adoption of synthetic biology and a paradigm shift towards precision/personalized medicine is dramatically expanding the need for high-quality, scalable DNA synthesis; as industry leader, Twist is uniquely positioned to supply these critical inputs, enabling exponential growth in its addressable market and fueling long-term top-line acceleration.
- Intensifying adoption of AI-driven drug discovery, coupled with swelling investment in next-gen biomanufacturing, is unleashing new high-value use cases for customized DNA and antibody libraries, making Twist the partner of choice for large pharma and synthetic bio innovators-driving not only higher ASPs but recurring multi-year contracts that can structurally increase revenue and margin visibility.
- Strategic investments in disruptive areas like DNA-based data storage, enabled by proprietary platform advances, are nearing commercial inflection; as these initiatives transition from R&D to revenue, Twist has the potential to open entirely new multi-billion-dollar markets, providing massive long-term upside and supporting both rapid revenue growth and superior earnings leverage.
Twist Bioscience Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- This narrative explores a more optimistic perspective on Twist Bioscience compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
- The bullish analysts are assuming Twist Bioscience's revenue will grow by 20.4% annually over the next 3 years.
- The bullish analysts are not forecasting that Twist Bioscience will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Twist Bioscience's profit margin will increase from -19.8% to the average US Biotechs industry of 18.0% in 3 years.
- If Twist Bioscience's profit margin were to converge on the industry average, you could expect earnings to reach $128.5 million (and earnings per share of $1.88) by about July 2029, up from -$81.3 million today.
- In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 78.6x on those 2029 earnings, up from -71.0x today. This future PE is greater than the current PE for the US Biotechs industry at 17.4x.
- The bullish analysts expect the number of shares outstanding to grow by 3.16% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.18%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Accelerating commoditization and intense competition in the synthetic DNA and NGS (Next-Generation Sequencing) markets may put sustained pricing pressure on Twist Bioscience's products, risking future erosion of gross margin and overall profitability.
- Ongoing negative operating margins and a projected adjusted EBITDA loss, despite improved gross margins, highlight the persistent risk that Twist Bioscience may remain unprofitable for an extended period, threatening future earnings and shareholder value if revenue growth slows or cost discipline falters.
- A reliance on continued rapid customer adoption for new and innovative products, especially in nascent markets like MRD (Minimal Residual Disease) and AI-driven drug discovery, introduces execution risk that could result in revenue shortfalls if uptake is slower than anticipated or competitors commercialize similar technologies more effectively.
- U.S. academic and industrial chemical funding environments remain uncertain and somewhat volatile, which, when coupled with broader macroeconomic trends such as rising interest rates and tighter credit, could constrain spending from key customers and reduce revenue predictability.
- Heightened geopolitical and regulatory risks, including the possibility of stricter bioethics regulations, evolving trade barriers, or supply chain disruptions for key reagents and components, could increase operational costs or delay production, potentially impacting both revenue and net income over the long term.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The assumed bullish price target for Twist Bioscience is $120.0, which represents up to two standard deviations above the consensus price target of $85.5. This valuation is based on what can be assumed as the expectations of Twist Bioscience's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $120.0, and the most bearish reporting a price target of just $36.0.
- In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $715.3 million, earnings will come to $128.5 million, and it would be trading on a PE ratio of 78.6x, assuming you use a discount rate of 7.2%.
- Given the current share price of $92.61, the analyst price target of $120.0 is 22.8% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Twist Bioscience?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Comments
0 commentsDisclaimer
AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
